Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Biochem Mol Toxicol ; 12(3): 167-73, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9522276

RESUMO

Employing thymidylate synthase (TS) (5, 10-CH2-H4PteGlu: dUMP C-methyltransferase, EC 2.1.1.45), a key target enzyme in chemotherapy, the biological activity of the beta-carboline-benzoquinolizidine alkaloid deoxytubulosine (DTB) isolated from the Indian medicinal plant Alangium lamarckii has been evaluated and assessed for the first time. The TS employed in the present studies was purified from Lactobacillus leichmannii. The DTB was demonstrated to exhibit potent cytotoxicity and inhibited the cell growth of L. leichmannii, and DTB potently inhibited TS activity (IC50 = 40 microM). The DTB concentrations > 80 microM resulted in a total loss of the TS activity, thus suggesting that the beta-carboline-benzoquinolizidine alkaloid is a promising potential antitumor agent. The DTB binding to TS appears to be irreversible and tight through a possible covalent linkage. Although DTB strongly binds to DNA, it is not known whether DTB binds to RNA associated with TS. Inhibition kinetics showed that TS has a Ki value of 7 x 10(-6) M for DTB and that the inhibition is a simple linear "noncompetitive" type.


Assuntos
Emetina/análogos & derivados , Emetina/farmacologia , Inibidores do Crescimento/farmacologia , Lactobacillus/enzimologia , Plantas Medicinais/química , Quinolizinas/farmacologia , Timidilato Sintase/antagonistas & inibidores , Timidilato Sintase/metabolismo , Tubercidina/farmacologia , Divisão Celular/efeitos dos fármacos , Emetina/toxicidade , Cinética , Lactobacillus/efeitos dos fármacos , Lactobacillus/crescimento & desenvolvimento , Modelos Moleculares , Ligação Proteica/efeitos dos fármacos , Quinolizinas/toxicidade , Tubercidina/toxicidade
2.
Antiviral Res ; 14(4-5): 215-25, 1990.
Artigo em Inglês | MEDLINE | ID: mdl-1965109

RESUMO

The toxicity and antiviral efficacy of carbocyclic 3-deazaadenosine (Cc3Ado) against respiratory syncytial (RSV) and parainfluenza type 3 (PIV3) virus infections were tested in tissue culture and in cotton rats. The mean median efficacious dose (ED50) of Cc3Ado in HEp2 cells against RSV and PIV3 was 9 and 14 micrograms/ml, respectively. These values were 85- and 55-fold less than the median inhibitory (toxic) dose (ID50) of Cc3Ado in this cell line (750 micrograms/ml), and similar to values obtained for ribavirin. Cc3Ado exhibited no significant antiviral activity against influenza A, influenza B, adeno type 5 or adeno type 7 viruses (all ED50 were greater than 1000 micrograms/ml). In cotton rats, animals given greater than or equal to 1 mg/kg/day Cc3Ado intraperitoneally on days 1, 2 and 3 after experimental challenge with virus, consistently had significant reductions in pulmonary RSV and PIV3 titers compared to pulmonary virus titers in comparably treated control animals. The minimum efficacious dose of ribavirin given under the same conditions was 30 mg/kg/day. Cc3Ado was also efficacious in cotton rats when given orally by gavage, or when different administration schedules were used. The median efficacious dose of Cc3Ado when given orally was 10 mg/kg/day. No significant toxic effects were noted in cotton rats, even in animals given 20 mg/kg daily for eight consecutive days.


Assuntos
Antivirais/toxicidade , Vírus da Parainfluenza 3 Humana/efeitos dos fármacos , Vírus Sinciciais Respiratórios/efeitos dos fármacos , Tubercidina/análogos & derivados , Replicação Viral/efeitos dos fármacos , Animais , Linhagem Celular , Avaliação Pré-Clínica de Medicamentos , Feminino , Humanos , Masculino , Vírus da Parainfluenza 3 Humana/crescimento & desenvolvimento , Infecções por Paramyxoviridae/tratamento farmacológico , Infecções por Paramyxoviridae/patologia , Ratos , Vírus Sinciciais Respiratórios/crescimento & desenvolvimento , Infecções por Respirovirus/tratamento farmacológico , Infecções por Respirovirus/patologia , Tubercidina/farmacologia , Tubercidina/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA